基于层次分析法的中药新药立项评估指标体系构建研究  

An index system of project evaluation for new drugs of TCM based on the analytic hierarchy process

作　　者：张婧波 李云飞[2] 邢花[1] 

机构地区：[1]沈阳药科大学工商管理学院,沈阳110016 [2]天士力控股集团有限公司研究院,天津300410

出　　处：《中国新药杂志》2016年第8期855-860,共6页Chinese Journal of New Drugs

摘　　要：通过项目引进合作的方式从大学、科研机构、医院等新药开发的公司获取新药项目资源是企业实现短期目标达成的方法。而长期以来,多数制药企业在选择项目时并没有经过谨慎客观论证,最终造成后续研发过程中出现许多问题的产生。本研究从实际出发,分别从政策环境、药品获批情况等方面有针对性的分析影响中药新药项目价值的指标因素,结合文献检索、专家咨询及调查问卷等方法综合分析确定中药新药立项评估指标,并通过层次分析法确定各指标权重,同时利用加权平均法确定专家打分权重进行纠偏处理,建立起较为科学合理的评估量化指标体系,以供相关制药企业参考和借鉴。The enterprises prefer to achieve the short-term strategy by cooperating with universities,scientific research institutions,hospitals and the Contract Research Organization. For a long period of time,most pharmaceutical enterprises make the decision without careful argument. That method will cause many problems in the process of RD. In this paper we studied the factors of RD research in aspects of policy environment,and situation of drug approved. Through the comprehensive analysis of the retrieved literature,expert consultation and the result of questionnaire methods,the index was determined,and the weight of each expert was calculated Then the final weight of every index of the evaluation system was obtained.

关 键 词：中药新药 立项评估 层次分析 指标 

分 类 号：R95[医药卫生—药学]